Prevalence and risk factors of depression and anxiety among patients with convulsive epilepsy in rural West China

Wang, Haijiao; Tan, Ge; Deng, Ying; He, Jun; He, Yu-jin; Zhou, Dong; Liu, Ling

doi:10.1111/ane.13016

Cited by 39 publications

(38 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition to impaired social behaviour, anxiety and depression are major problems for patients with Dravet syndrome (Chen et al, ; Jain, Subendran, Smith, & Widjaja, ; Wang et al, ). Although AEDs such as valproate, lamotrigine, clobazam, gabapentin and oxcarbazepine have been reported to improve these behavioural co‐morbidities, a number of others have been shown to progressively deteriorate them (Chen, Choi, et al, ).…”

Section: Discussionmentioning

confidence: 99%

Cannabidiol improves survival and behavioural co‐morbidities of Dravet syndrome in mice

Patra

Serafeimidou‐Pouliou

Bazelot

et al. 2020

British J Pharmacology

View full text Add to dashboard Cite

Background and Purpose: Dravet syndrome is a severe, genetic form of paediatric epilepsy associated with premature mortality and co-morbidities such as anxiety, depression, autism, motor dysfunction and memory deficits. Cannabidiol is an approved anticonvulsive drug in the United States and Europe for seizures associated with Dravet syndrome in patients 2 years of age and older. We investigated its potential to prevent premature mortality and improve associated co-morbidities. Experimental Approach:The efficacy of sub-chronic cannabidiol administration in two mouse models of Dravet syndrome was investigated. The effect of cannabidiol on neonatal welfare and survival was studied using Scn1a −/− mice. We then used a hybrid, heterozygote Scn1a +/− mouse model to study the effect of cannabidiol on survival and behavioural co-morbidities: motor deficits (rotarod and static-beam test), gait abnormality (gait test), social anxiety (social interaction test), anxiety-like (elevated plus maze) and depressive-like behaviours (sucrose preference test) and cognitive impairment (radial arm maze test). Key Results:In Scn1a −/− mice, cannabidiol increased survival and delayed worsening of neonatal welfare. In Scn1a +/− mice, chronic cannabidiol administration did not show any adverse effect on motor function and gait, reduced premature mortality, improved social behaviour and memory function, and reduced anxiety-like and depressive-like behaviours. Conclusion and Implications:We are the first to demonstrate a potential diseasemodifying effect of cannabidiol in animal models of Dravet syndrome. Cannabidiol treatment reduced premature mortality and improved several behavioural comorbidities in Dravet syndrome mice. These crucial findings may be translated into human therapy to address behavioural co-morbidities associated with Dravet syndrome.

show abstract

Section: Discussionmentioning

confidence: 99%

Cannabidiol improves survival and behavioural co‐morbidities of Dravet syndrome in mice

Patra

Serafeimidou‐Pouliou

Bazelot

et al. 2020

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…While the C-NDDI-E is not a substitute for clinical interview or Diagnostic and Statistical Manual (4th ed.) diagnosis, it is a reliable, validated, and widely used self-reported measure of depression in mainland China [21,24]. The Chinese version of the GAD-7 has also been validated in Chinese [25].…”

Section: Discussionmentioning

confidence: 99%

“…This study would add new knowledge on correlates of depressive and anxiety symptoms among PWE, apart from previous studies' findings mainly on sociodemographic and epilepsy-related factors of these psychiatric comorbidities [17,21].…”

Section: Introductionmentioning

confidence: 95%

A cross-sectional study on the association of serum uric acid levels with depressive and anxiety symptoms in people with epilepsy

Zhong

Chen

et al. 2021

BMC Psychiatry

View full text Add to dashboard Cite

Background High serum uric acid (SUA) levels may provide protection against depression and anxiety through its defensive role in oxidative damage. The aim of this study was to test the hypothesis of the independent associations of lower SUA levels with depressive and anxiety symptoms among patients with epilepsy (PWE). Methods A cross-sectional study was performed among 320 PWE aged ≥18 years old in Northeast China. The Neurological Disorders Depression Inventory for Epilepsy (NDDI-E; Chinese version) and the Generalized Anxiety Disorder-7 scale (GAD-7; Chinese version) were used as screening tools for depressive and anxiety symptoms for PWE. Serum uric acid levels were measured. The associations of SUA levels with depressive and anxiety symptoms were assessed by using binary logistic regression models, with adjustment for the related risk factors (P< 0.05). Results Lower SUA tertiles were significantly associated with higher C-NDDI-E and GAD-7 scores compared with the higher two tertiles (p=0.001, and p= 0.002). Patients with depressive symptoms exhibited significantly lower SUA levels compared to those without depressive symptoms (p< 0.001). SUA levels of patients with anxiety symptoms were significantly lower than those of patients without anxiety symptoms (p< 0.001). The first and second SUA tertiles were associated with depressive symptoms, with the third tertile group as the reference group, after adjusting for confounders (first tertile: OR = 4.694, 95% CI = 1.643~ 13.413, P = 0.004; second tertile: OR = 3.440, 95% CI = 1.278~9.256, P = 0.014). However, The first and second SUA tertiles were not associated with the risk of anxiety symptoms compared with the third tertile in the adjusted logistic regression model (First tertile: OR = 1.556, 95% CI = 0.699~3.464, P = 0.279; second tertile: OR = 1.265, 95% CI = 0.607~2.635, P = 0.530). Conclusion We found that lower SUA levels were independently associated with depressive symptoms but not with anxiety symptoms among PWE. Further well-designed prospective cohort studies are required to determine the causality of the associations and to further clarify the mechanisms of SUA in depressive symptoms.

show abstract

“…The prevalence of mental disorders has been dramatic in China in recent decades [20]. And the prevalence of anxiety in rural China is higher than that in urban areas [21,22]. Moreover, Henan is the most populous province with 48.3% of the rural population in 2018 [19].…”

Section: Introductionmentioning

confidence: 99%

Dose-response association of sleep quality with anxiety symptoms in Chinese rural population: the Henan rural cohort

et al. 2020

View full text Add to dashboard Cite

Background: The epidemiological evidence on the association of sleep quality on anxiety symptoms has been inconclusive. This study aimed to explore the association between sleep quality and anxiety symptoms in rural Chinese population and investigate whether age, lifestyles, and chronic diseases modified this association. Methods: A total of 27,911 participants aged 18-79 years from the Henan Rural Cohort Study were included in the study. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI) scale. Poor sleep quality was defined as PSQI ≥6. Anxiety symptoms were evaluated with the two-item generalized anxiety disorder scale (GAD-2). Individual with score ≥ 3 was viewed as having anxiety symptoms. Logistic regression and restricted cubic spline were conducted to examine the association of sleep quality with anxiety symptoms. Results: Altogether, 6087 (21.80%) participants were poor sleepers and 1557 (5.58%) had anxiety symptoms. The odds of anxiety were increased with increment of PSQI score after fitting restricted cubic splines. The poor sleep quality was associated with a higher possibility of anxiety symptoms [odd ratio (OR): 4.60, 95% confidence interval (CI): 3.70-5.72] in men, and (OR: 3.56, 95% CI: 3.10-4.09) in women for multivariable analysis. Further, stratified analyses showed that the effect of sleep quality on anxiety symptoms could be modified by age, marital status, smoking status, drinking status, hypertension, and type 2 diabetes mellitus. Conclusions: A dose-response association between PSQI score and anxiety symptoms was found. In addition, the relationship between poor sleep quality and greater anxiety symptoms was observed in this rural population, especially in participants aged ≥60 years and those with unhealthy habits or had a chronic disease. Trial registration: The trial was prospectively registered on July 6, 2015 and available online at ClinicalTrials.gov ID: ChiCTR-OOC-15006699.

show abstract

Prevalence and risk factors of depression and anxiety among patients with convulsive epilepsy in rural West China

Cited by 39 publications

References 37 publications

Cannabidiol improves survival and behavioural co‐morbidities of Dravet syndrome in mice

Cannabidiol improves survival and behavioural co‐morbidities of Dravet syndrome in mice

A cross-sectional study on the association of serum uric acid levels with depressive and anxiety symptoms in people with epilepsy

Dose-response association of sleep quality with anxiety symptoms in Chinese rural population: the Henan rural cohort

Contact Info

Product

Resources

About